Elie Traer

8.7k total citations · 1 hit paper
64 papers, 1.8k citations indexed

About

Elie Traer is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Elie Traer has authored 64 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 35 papers in Molecular Biology and 17 papers in Genetics. Recurrent topics in Elie Traer's work include Acute Myeloid Leukemia Research (39 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Protein Degradation and Inhibitors (10 papers). Elie Traer is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Protein Degradation and Inhibitors (10 papers). Elie Traer collaborates with scholars based in United States, India and Canada. Elie Traer's co-authors include Xiaodong Wang, Qing Zhong, Wenhua Gao, Deepak Nijhawan, Fenghe Du, Min Fang, Jeffrey Tyner, Brian Druker, Jennifer Dunlap and Stephen M. Prescott and has published in prestigious journals such as Journal of Biological Chemistry, Genes & Development and SHILAP Revista de lepidopterología.

In The Last Decade

Elie Traer

61 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation

2003 502 citations Deepak Nijhawan, Min Fang et al. Genes & Development profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elie Traer United States	21	1.1k	666	353	268	252	64	1.8k
Kimberley Joanne Hatfield Norway	26	1.0k 0.9×	998 1.5×	378 1.1×	287 1.1×	288 1.1×	57	1.8k
Aaron J. Donner United States	15	1.1k 1.1×	655 1.0×	354 1.0×	250 0.9×	232 0.9×	18	2.1k
Rui-Yu Wang United States	14	964 0.9×	472 0.7×	669 1.9×	243 0.9×	262 1.0×	20	1.7k
Frédèrique Verdier France	20	771 0.7×	464 0.7×	504 1.4×	331 1.2×	142 0.6×	36	1.6k
Richard L. Darley United Kingdom	23	955 0.9×	676 1.0×	275 0.8×	160 0.6×	189 0.8×	52	1.6k
Cong Peng China	20	655 0.6×	578 0.9×	215 0.6×	288 1.1×	139 0.6×	51	1.3k
Phuong L. Doan United States	21	624 0.6×	564 0.8×	258 0.7×	283 1.1×	199 0.8×	57	1.4k
Armin Zebisch Austria	19	895 0.8×	411 0.6×	331 0.9×	143 0.5×	302 1.2×	57	1.5k
Wen-Mei Yu United States	23	1.3k 1.2×	379 0.6×	298 0.8×	146 0.5×	306 1.2×	30	1.8k
Véronique Mansat‐De Mas France	25	1.3k 1.2×	1.4k 2.2×	428 1.2×	546 2.0×	280 1.1×	57	2.5k

Countries citing papers authored by Elie Traer

Since Specialization

Citations

This map shows the geographic impact of Elie Traer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elie Traer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elie Traer more than expected).

Fields of papers citing papers by Elie Traer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elie Traer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elie Traer. The network helps show where Elie Traer may publish in the future.

Co-authorship network of co-authors of Elie Traer

This figure shows the co-authorship network connecting the top 25 collaborators of Elie Traer. A scholar is included among the top collaborators of Elie Traer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elie Traer. Elie Traer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravandi‐Kashani, Farhad, Aaron D. Goldberg, Elie Traer, et al.. (2023). PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES. Hematological Oncology. 41(S2). 834–835. 2 indexed citations

Traer, Elie, et al.. (2023). Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia. Cancers. 15(14). 3589–3589. 14 indexed citations

Vachhani, Pankit, Abdulraheem Yacoub, Elie Traer, et al.. (2023). Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies. Blood. 142(Supplement 1). 4554–4554. 1 indexed citations

Hong, Decheng, Thomas G. DeLoughery, Curtis A. Lachowiez, et al.. (2023). Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia. Blood. 142(Supplement 1). 2829–2829.

Gosline, Sara J.C., Cristina E. Tognon, Sunil K. Joshi, et al.. (2022). Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML. Clinical Proteomics. 19(1). 30–30. 14 indexed citations

Borate, Uma, Andy Kaempf, Jessica Minnier, et al.. (2021). FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy. Blood. 138(Supplement 1). 1269–1269. 2 indexed citations

Fletcher, Luke B., Sunil K. Joshi, & Elie Traer. (2020). <p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>. Cancer Management and Research. Volume 12. 151–163. 23 indexed citations

Fletcher, Luke, Sunil Kumar Joshi, & Elie Traer. (2020). Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. SHILAP Revista de lepidopterología. 1 indexed citations

Joshi, Sunil K., Jamie M. Keck, Christopher A. Eide, et al.. (2020). ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. 34(10). 2798–2804. 11 indexed citations

10.

Lachowiez, Curtis A., Rachel J. Cook, Brandon Hayes‐Lattin, et al.. (2019). Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years. Hematology/Oncology and Stem Cell Therapy. 12(2). 105–109. 5 indexed citations

11.

Javidi‐Sharifi, Nathalie, Jacqueline Martinez, Isabel A. English, et al.. (2019). FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. eLife. 8. 53 indexed citations

12.

Cortes, Jörge E., Daniel J. DeAngelo, Harry P. Erba, et al.. (2018). Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 26–26. 26 indexed citations

13.

Cortes, Jörge E., Elie Traer, Eunice S. Wang, et al.. (2017). IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 130. 1312–1312. 7 indexed citations

14.

Bandyopadhyay, Shovik, Junjie Li, Elie Traer, et al.. (2017). Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS ONE. 12(7). e0179558–e0179558. 46 indexed citations

15.

Traer, Elie, Jacqueline Martinez, Nathalie Javidi‐Sharifi, et al.. (2016). FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Research. 76(22). 6471–6482. 96 indexed citations

16.

Javidi‐Sharifi, Nathalie, Elie Traer, Jacqueline Martinez, et al.. (2014). Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75(5). 880–891. 86 indexed citations

17.

Braun, Theodore P., et al.. (2014). Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. Leukemia Research Reports. 4(1). 8–11. 3 indexed citations

18.

Traer, Elie & Michael W. Deininger. (2010). How Much and How Long: Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 10. S20–S26. 6 indexed citations

19.

Nijhawan, Deepak, Min Fang, Elie Traer, et al.. (2003). Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes & Development. 17(12). 1475–1486. 502 indexed citations breakdown →

20.

Traer, Elie, et al.. (1998). The Cloning and Characterization of a Novel Human Diacylglycerol Kinase, DGKι. Journal of Biological Chemistry. 273(49). 32746–32752. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact